Lots of interesting abstracts and cases were submitted for TCTAP & AP VALVES 2020 Virtual. Below are accepted ones after thoroughly reviewed by our official reviewers. Don¡¯t miss the opportunity to explore your knowledge and interact with authors as well as virtual participants by sharing your opinion!
* The E-Science Station is well-optimized for PC.
We highly recommend you use a desktop computer or laptop to browse E-posters.
ABS20191030_0012
| Basic Science, Animal Models and Preclinical Studies | |
| Intravenously Delivered Mesenchymal Stem Cells Prevent MVO Formation After Cardiac Ischemia/Reperfusion Injury | |
| Jun Xie1 | |
| Nanjing Drum Tower Hospital, China1 | |
|
Background:
Background: MVO was identified as an independent risk factor for prognosis in patients with ST-segmentelevation myocardial infarction (STEMI). Inflammatory induced by ischemia and reperfusion injury (I/R injury) is thought as one major mechanisms for MVO formation. A proper strategy with decreased tissue inflammatory after revascularization would be benefit to prevent MVO formation and better prognosis. Mesenchymal stromal cells (MSCs) are a unique stromal cell type that confers immunomodulatory effect in several inflammatory related disease. Here we investigate whether intravenously and immediately delivered MSC could be used as potential therapeutic method to prevent MVO formation by inflammatory alternation.
|
|
|
Methods:
Myocardial ischemia/reperfusion (I/R) model was established on adult female experimental mini porcine. Immediately after reperfusion, animals were allocated to receive 1¡¿106cells/kg MSCs or vehicles intravenously. Magnetic resonance imaging was performed 2 days and 7 days after operation to determine infarct size (IS), micro-vascular obstruction (MVO) and cardiac function after I/R injury. Flow cytometry experiments were performed in order to measure the changes of immune cells proportion in blood and tissues following myocardial I/R injury.
|
|
|
Results:
The CMR in 2days after operation revealed that infarct size in vehicle group was significantly larger than that in MSC group. Meanwhile, the MVO area in MSC group was significantly smaller than that in vehicle group. The CMR in 7 days after operation revealed the animals with MSC have smaller infarct size, better EF and larger SV compared with control animals. The flow cytometry analysis showed the animals with allograft MSC delivering had decreased NK cells in the blood at day 1 as well as in the heart, kidney and liver tissue compared with those in control animals.
|
|
|
Conclusion:
Here we observed that allograft MSC delivering intravenously after myocardium I/Reinjury could attenuate MVO formation in porcine by NK cells depression. Our work demonstrated that allograft MSC delivering immediately and intravenously could be a potential novel therapeutic approach for MVO formation in STEMI patients.
|
|
0